16 January 2014
ValiRx Plc
('ValiRx' or the 'Company')
Issue of equity
The Company announces that it has issued 9,801,829 new ordinary shares in the Company at a price of 0.328 pence per share in lieu of £32,150 services provided to the Company.
Application has been made to the London Stock Exchange for the new ordinary shares to be admitted to trading on AIM on or around the 21 January 2014. The new ordinary shares will rank pari passu with the existing ordinary shares.
TVR
In accordance with the Disclosure and Transparency Rules (DTR 5.6.1R) the Company hereby notifies the market that immediately following Admission its issued share capital will consist of 2,921,043,530 ordinary shares of 0.1p each. The Company does not hold any shares in treasury. Shareholders may use this figure as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure and Transparency Rules.
For more information, please contact:
ValiRx plc |
Tel: +44 (0)20 3008 4416 |
Dr Satu Vainikka
|
|
|
|
Cairn Financial Advisers LLP (Nominated Adviser) |
Tel: +44 (0)20 7148 7900 |
Liam Murray / Avi Robinson
|
|
|
|
Daniel Stewart & Company Plc (Broker) |
Tel: +44 (0)20 7776 6550 |
David Hart / Mark Treharne
|
|
Peckwater PR |
Tel: +44 (0)7879 458 364 |
Tarquin Edwards |